STAT+: Seattle scientists launch $95 million AI biology effort

Phase 3negativeNegative

AI Analysis

Summary

Ultragenyx's pivotal Phase 3 trial failed. Seattle scientists launch $95 million AI biology effort; FDA updates approach to regulating unproven stem cell therapies.

Clinical Trial Data

Phase

Primary Endpoint

Not Met

Outcome Details

Pivotal Phase 3 trial failed

Importance:7/10

Sentiment:

-0.70

Phase_3_failureUltragenyxAI_biologystem_cellsFDA_regulation

Related Companies

$RARE

Read the original article

Published by STAT News on September 3, 2026 2:39 PM

Read Original